Evotec SE (FRA:EVT)
Market Cap | 1.14B |
Revenue (ttm) | 777.33M |
Net Income (ttm) | -155.53M |
Shares Out | n/a |
EPS (ttm) | -0.88 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 169,862 |
Average Volume | 1,671,752 |
Open | 6.51 |
Previous Close | 6.43 |
Day's Range | 6.42 - 6.56 |
52-Week Range | 5.06 - 10.62 |
Beta | n/a |
RSI | 39.45 |
Earnings Date | Aug 13, 2025 |
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic disease... [Read more]
Financial Performance
In 2024, Evotec SE's revenue was 796.97 million, an increase of 1.99% compared to the previous year's 781.43 million. Losses were -196.08 million, 133.7% more than in 2023.
Financial StatementsNews
Evotec SE (EVO) Q2 2025 Earnings Call Transcript
Evotec SE 2025 Q2 - Results - Earnings Call Presentation
Evotec SE reports 1H results
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ: EVO) is projected to report quarterly loss at $0.12 per share on revenue of $238.88 million. • Elbit Systems (NASDAQ: ESLT) is projected to repo...

Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution
Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductionsReporting segment formerly known as Shared R&D renamed to Discovery & Prec...

Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution
Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions Reporting segment formerly known as Shared R&D renamed to Discovery & Pre...

Evotec SE's H1 2025 Results: Strategy Execution Shines Brightly
Evotec SE navigates a mixed financial landscape in H1 2025, balancing revenue dips with strategic advancements and promising growth in biologics. Jetzt den vollständigen Artikel lesen

EQS-News: Evotec SE reports H1 2025 results: Strong progress on strategy execution
EQS-News: Evotec SE / Key word(s): Half Year Report/Half Year Results Evotec SE reports H1 2025 results: Strong progress on strategy execution 13.08.2025 / 07:00 CET/CEST The issuer is solely responsi...
An Overview of Evotec's Earnings
Evotec (NASDAQ: EVO) is gearing up to announce its quarterly earnings on Wednesday, 2025-08-13. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

Evotec SE to announce first half-year results 2025 on 13 August 2025
HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim r...

Evotec SE to announce first half-year results 2025 on 13 August 2025
HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim r...

EQS-News: Evotec SE to announce first half-year results 2025 on 13 August 2025
EQS-News: Evotec SE / Key word(s): Half Year Results Evotec SE to announce first half-year results 2025 on 13 August 2025 06.08.2025 / 09:52 CET/CEST The issuer is solely responsible for the content o...

Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site
HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-bin...

Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site
HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-bin...

Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site
Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to SandozUnder the proposed deal Evotec would transfer biosimilar manufacturing capa...

Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site
Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz Under the proposed deal Evotec would transfer biosimilar manufacturing cap...

EQS-News: Evotec and Sandoz evolve their strategic partnership and agree on potential sale of Just – Evotec Biologics Toulouse site
EQS-News: Evotec SE / Key word(s): Agreement Evotec and Sandoz evolve their strategic partnership and agree on potential sale of Just – Evotec Biologics Toulouse site 30.07.2025 / 07:16 CET/CEST The i...

EQS-Adhoc: Evotec SE and Sandoz AG planning potential sale of Just – Evotec Biologics Toulouse site
EQS-Ad-hoc: Evotec SE / Key word(s): Agreement Evotec SE and Sandoz AG planning potential sale of Just – Evotec Biologics Toulouse site 30-Jul-2025 / 07:14 CET/CEST Disclosure of an inside information...

EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Evotec SE Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 23.07.202...
Evotec: Recovery Seems To Be Beginning

Evotec, Webull And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Monday. Shares of Evotec SE (NASDAQ: EVO) fell sharply in pre-market trading after the company updated i...

Evotec, Webull And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Monday.
Evotec lowers FY25 revenue forecast, keeps profit targets & confirms long-term 2028 outlook

Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix
Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec's differentiated platformsHigh-margin technology license revenu...

Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix
Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec's differentiated platforms High-margin technology license reven...